Small Pharma’s first phase clinical trials prove promising for DMT-assisted therapy

Our CMSO Carol Routledge spoke to Mental Health Today about Small Pharma and its history with psychedelic research, Phase I clinical trials and the research around a safe, well-tolerated DMT dose, as well as what’s on the horizon for Small Pharma and psychedelic-assisted therapy 

On psychedelic-assisted therapy as a whole,  Dr Routledge had lots to say including a discussion on the potential of psychedelic-assisted therapy to address the unmet mental health needs of  millions of people.

I’ve worked in the pharmaceutical industry for a long time. I have worked on SSRIs in the past. I do think SSRIs are effective, but clearly in a very different way to psychedelic-assisted therapy. But they are not effective in all patients…And although effective, I don’t really think SSRIs get to the root cause. Whereas I do believe that psychedelic assisted therapy potentially could.”


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: